[ad_1] By Shefali Luthra, Kaiser Health News When the Amarin biopharmaceutical company released its latest clinical trial results this fall, it caused buzz and controversy in the medical community by suggesting that …
Read More »
[ad_1] Amarin Corporation plc (NASDAQ: AMRN) shares were falling Monday following the presentation of detailed primary results from the the late-stage REDUCE-IT study that evaluated Vascepa, held at a late-breaking session at …
Read More »
[ad_1] Results from the 8,179-subject REDUCE-IT study evaluation Amarin's (NASDAQ: AMRN) Vascepa (icosapent ethyl) in statin-treated adults with elevated cardiovascular (CV) risk showed a significant treatment effect. The data were presented at …
Read More »
[ad_1] Amarin made waves in September, announcing her victory in the test-reduction of her purified fish oil product, Vascepa. The comprehensive data, presented yesterday at the meeting of the American Heart Association …
Read More »